{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:26:42Z","timestamp":1788877602983,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Fluoresc"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vonoprazan (VON) has been approved recently via US-FDA in 2015 as the first in class of potassium competitive acid blocker group. VON is used\u00a0for management of GIT ulcer, reflux\u00a0esophagitis and for eradication of\u00a0Helicobacter pylori. So, the first spectrofluorimetric method was developed for estimation of VON in real human plasma and content uniformity test. The fluorimetric methodology based on reaction of secondary amine group in VON with benzofurazan (0.05% w\/v NBD-Cl) reagent as nucleophilic substitution reaction in alkaline medium (0.1\u00a0M borate buffer pH 8.2) to produce highly fluorescent product measure at 530\u00a0nm after excitation at 465\u00a0nm. The linear calibration range was found 15 to 200\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> with lower limit of quantitation (LOQ) equal to 8.57\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup>. The method was successfully applied for estimation of VON in pharmacokinetic (PK) and content uniformity studies. The maximum plasma concentration was found\u00a0to be (C<jats:sub>max<\/jats:sub>) 71.03\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> after maximum time (t<jats:sub>max<\/jats:sub>) equal to 1.5\u2009\u00b1\u20090.15\u00a0h. The presented strategy also applied to ensure concentration of drug in each tablet using content uniformity test with high percent of recovery 100.05\u2009\u00b1\u20090.66. The proposed method was established for clinical laboratories and therapeutic drug monitoring studies.<\/jats:p>","DOI":"10.1007\/s10895-022-02979-2","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:06:15Z","timestamp":1654589175000},"page":"1725-1732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ultra-Sensitive Fluorimetric Method for the First Estimation of Vonoprazan in Real Human Plasma and Content Uniformity Test"],"prefix":"10.1007","volume":"32","author":[{"given":"Roshdy E.","family":"Saraya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser F.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid E.","family":"Eltukhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher I.","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"2979_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Vonoprazan: first global approval. Drugs 75:439\u2013443. https:\/\/doi.org\/10.1007\/s40265-015-0368-z","journal-title":"Drugs"},{"key":"2979_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/bio.3688","volume":"34","author":"SA Hussein","year":"2019","unstructured":"Hussein SA, Salman BI, Ali MF, Marzouq MA (2019) Development of sensitive benzofurazan-based spectrometric methods for analysis of spectinomycin in vials and human biological samples. Luminescence 34:895\u2013902. https:\/\/doi.org\/10.1002\/bio.3688","journal-title":"Luminescence"},{"key":"2979_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.saa.2015.12.012","volume":"157","author":"MA Hammad","year":"2016","unstructured":"Hammad MA, Omar MA, Salman BI, Derayea SM (2016) Highly sensitive spectrofluorimetric method for determination of doxazosin through derivatization with fluorescamine; Application to content uniformity testing. Spectrochim Acta A 157:55\u201360. https:\/\/doi.org\/10.1016\/j.saa.2015.12.012","journal-title":"Spectrochim Acta A"},{"key":"2979_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.microc.2019.03.002","volume":"147","author":"MA Marzouq","year":"2019","unstructured":"Marzouq MA, Salman BI, Hussein SA, Ali MF (2019) Hantzsch reaction approach for determination of teicoplanin and vancomycin in real human plasma: Application to pharmaceutical preparations and to synthetic mixture with rifampicin for drug-resistant strain of Staphylococcus aureus. Microchem J 147:25\u201329. https:\/\/doi.org\/10.1016\/j.microc.2019.03.002","journal-title":"Microchem J"},{"key":"2979_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jchromb.2016.01.051","volume":"1015","author":"T Yoneyama","year":"2016","unstructured":"Yoneyama T, Teshima K, Jinno F, Kondo T, Asahi S (2016) A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry. J Chromatog B 1015:42\u201349. https:\/\/doi.org\/10.1016\/j.jchromb.2016.01.051","journal-title":"J Chromatog B"},{"key":"2979_CR6","first-page":"535","volume":"12","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Huang J, Xu Y, Zhao J, Wang Q (2018) Determination of vonoprazan pyroglutamate and vonoprazan fumarate by HPLC. China Pharma 12:535\u2013538","journal-title":"China pharma"},{"key":"2979_CR7","doi-asserted-by":"publisher","first-page":"103254","DOI":"10.1016\/j.arabjc.2021.103254","volume":"14","author":"SD Al-Qahtani","year":"2021","unstructured":"Al-Qahtani SD, Al-nami SY (2021) Copper oxide nanopowder modified carbon paste electrode for the voltammetric assay of vonoprazan. Arab J Chem 14:103254. https:\/\/doi.org\/10.1016\/j.arabjc.2021.103254","journal-title":"Arab J Chem"},{"key":"2979_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.microc.2018.12.018","volume":"145","author":"BI Salman","year":"2019","unstructured":"Salman BI, Hussein SA, Ali MF, Marzouq MA (2019) Innovative ultra-sensitive spectrofluorimetric method for nanogram detection of doripenem monohydrate in human plasma, urine and pharmaceutical formulation. Microchem J 145:959\u2013965. https:\/\/doi.org\/10.1016\/j.microc.2018.12.018","journal-title":"Microchem J"},{"key":"2979_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/bio.3590","volume":"34","author":"BI Salman","year":"2019","unstructured":"Salman BI, Ali MF, Marzouq MA, Hussein AS (2019) Utility of the fluorogenic characters of benzofurazan for analysis of tigecycline using spectrometric technique; application to pharmacokinetic study, urine and pharmaceutical formulations. Luminescence 34:175\u2013182. https:\/\/doi.org\/10.1002\/bio.3590","journal-title":"Luminescence"},{"key":"2979_CR10","doi-asserted-by":"publisher","first-page":"44773","DOI":"10.1039\/C7RA08106E","volume":"7","author":"MA Omar","year":"2017","unstructured":"Omar MA, Hammad MA, Awad M (2017) Utility of 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole for development of a highly sensitive stability indicating spectrofluorimetric method for determination of salmeterol xinafoate; application to human plasma. RSC Adv 7:44773\u201344779. https:\/\/doi.org\/10.1039\/C7RA08106E","journal-title":"RSC Adv"},{"key":"2979_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10895-008-0433-z","volume":"19","author":"IA Darwish","year":"2009","unstructured":"Darwish IA, Amer SM, Abdine HH, Al-Rayes LI (2009) Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. J Fluoresc 19:463\u2013471. https:\/\/doi.org\/10.1007\/s10895-008-0433-z","journal-title":"J Fluoresc"},{"key":"2979_CR12","unstructured":"U.S. Pharmacopoeial Convention (2011) (905) Uniformity of Dosage Units. Stage 6 Harmonization 3:4\u20136"},{"key":"2979_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10895-010-0693-2","volume":"21","author":"M Walsh","year":"2011","unstructured":"Walsh M, Belal F, El-Enany N, Elmansi H (2011) Spectrofluorimetric determination of paroxetine HCl in pharmaceuticals via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole (NBD-Cl). J Fluoresc 21:105\u2013112. https:\/\/doi.org\/10.1007\/s10895-010-0693-2","journal-title":"J Fluoresc"},{"key":"2979_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0014-827X(02)00013-7","volume":"58","author":"ES Aktas","year":"2003","unstructured":"Aktas ES, Ersoy L, Sag\u0131rl\u0131 O (2003) A new spectrofluorimetric method for the determination of lisinopril in tablets. Il Farmaco 58:165\u2013168. https:\/\/doi.org\/10.1016\/S0014-827X(02)00013-7","journal-title":"Il Farmaco"},{"key":"2979_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10895-010-0759-1","volume":"21","author":"SE Kepekci","year":"2011","unstructured":"Kepekci SE, \u00d6nal E (2011) Spectrofluorimetric methods for the determination of gemifloxacin in tablets and spiked plasma samples. J Fluoresc 21:1001\u20131007. https:\/\/doi.org\/10.1007\/s10895-010-0759-1","journal-title":"J Fluoresc"},{"key":"2979_CR16","unstructured":"International Conference on Harmonization (2005) Topic Q2 (R1) Validation of analytical procedures: text and methodology"},{"key":"2979_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4155\/bio.13.298","volume":"6","author":"D Zimmer","year":"2014","unstructured":"Zimmer D (2014) New US-FDA draft guidance on bio-analytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanalysis 6:13\u201319. https:\/\/doi.org\/10.4155\/bio.13.298","journal-title":"Bioanalysis"},{"key":"2979_CR18","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, Yoneyama T, Jenkins H, Ashida K, Irie S, Taubel J (2015) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol 6:e94. https:\/\/doi.org\/10.1038\/ctg.2015.18","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Journal of Fluorescence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-022-02979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10895-022-02979-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-022-02979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T08:17:16Z","timestamp":1661329036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10895-022-02979-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1007\/s10895-022-02979-2","relation":{},"ISSN":["1053-0509","1573-4994"],"issn-type":[{"value":"1053-0509","type":"print"},{"value":"1573-4994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Plasma samples were collected and carried out according to (ethical standards of the responsible committee on human experimentation) (institutional and national) and with Helsinki Declaration of 1975, as revised in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The human experimental carried out at human healthy volunteers according to Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}